
Pandemic Influenza Preparedness Framework

ANNUAL PROGRESS REPORT

1 January – 31 December 2018



World Health
Organization

WHO/WHE/IHM/PIP/2019.1

© World Health Organization 2019.

Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Pandemic Influenza Preparedness Framework: Progress Report 2018. Geneva: World Health Organization; 2019 (WHO/WHE/IHM/PIP/2019.1). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

INTRODUCTION

The **Pandemic Influenza Preparedness (PIP) Framework** is an innovative public health instrument that brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. The key goals include: to improve and strengthen the sharing of influenza viruses with human pandemic potential; and to increase the access of developing countries to vaccines and other pandemic response supplies.

The Framework includes a benefit-sharing mechanism called the Partnership Contribution (PC). The PC is collected as an annual cash contribution from influenza vaccine, diagnostic, and pharmaceutical manufacturers that use the WHO Global Influenza Surveillance and Response System (GISRS). Funds are allocated for: (a) pandemic preparedness capacity building; (b) response activities during the time of a pandemic; and (c) PIP Secretariat for the management and implementation of the Framework.

For pandemic preparedness capacity building, activities are implemented according to six outputs under one outcome in the High Level Implementation Plan (HLIP) II 2018-2023. The technical and financial investments of countries and other partners, including GISRS, play a critical role in advancing pandemic preparedness alongside PC investments. Collectively, resources are used to strengthen pandemic preparedness systems, knowledge and capacities. We thank countries and partners for their important role and contribution. The progress made and successes achieved are a result of joint collaboration on common objectives.

This report addresses the recommendation from the 2016 PIP Review that WHO develop a progress report that presents overall success metrics and infographics to illustrate progress in PIP Framework implementation. The report is published twice a year: once as a semi-annual report and once as an annual report. Technical and financial implementation for HLIP II and the PIP Secretariat are presented. Milestones are measured every six months and indicators are measured yearly. All data are presented cumulatively from 1 January 2018.

For financial implementation, progress is reported against biennial workplan allocations. Figures presented exclude WHO Programme Support Costs (PSC) unless otherwise stated. For the mid-year reports, income, expenditures and encumbrances are presented, and are based on WHO's financial tracking system (GSM). For annual reports, income and expenditures are presented, in line with the yearly WHO Interim Certified Financial Statement (ICFS).

Many staff across WHO Clusters and Departments in all Major Offices support the implementation of the PIP Framework. Without their work, dedication and collaboration, there would be no progress to report on. We extend our sincere thanks to these staff for their invaluable work.

The report is structured as a series of infographics as follows:

- **PIP Framework implementation overview** (pages 6 – 7)
- **Technical and financial implementation progress** (pages 8 – 18)
- **Financial report including ICFS - Annex A** (*reported annually only*)


ACRONYMS & ABBREVIATIONS

AFR	WHO African Region	NITAG	National Immunization Technical Advisory Groups
AG	Advisory Group	NRA	National Regulatory Authority
AMR	WHO Region of the Americas	NVDP	National Vaccine Deployment Plan
BM	Biological Material	PC	Partnership Contribution
BOD	Burden of Disease	PCR	Polymerase Chain Reaction
CC	Collaborating Centre	PIP	Pandemic Influenza Preparedness
CRP	Collaborative Registration Procedure	PIRM	Pandemic Influenza Risk Management
CVV	Candidate Vaccine Virus	PISA	Pandemic Influenza Severity Assessment
DFID	Department for International Development (United Kingdom)	PQ	Prequalification
DG	Director-General	PSC	Programme Support Costs
EB	Executive Board	QMS	Quality Management Systems
EMR	WHO Eastern Mediterranean Region	RCCE	Risk Communications and Community Engagement
DEP	Planning for Deployment	REG	Regulatory Capacity Building
EQAP	External Quality Assessment Programme	RO	Regional Office
EUR	WHO European Region	RRT	Rapid Response Teams
GIP	Global Influenza Programme	SAGE	Strategic Advisory Group of Experts
GISRS	Global Influenza Surveillance and Response System	SARI	Severe Acute Respiratory Infection
GSD	Genetic Sequence Data	SEAR	WHO South-East Asia Region
HAI	Human Animal Interface	SFP	Shipping Fund Project
HLIP	High-Level Implementation Plan	SMTA2	Standard Material Transfer Agreement 2
ICFS	Interim Certified Financial Statement	TAG	Technical Advisory Group
IDP	Institutional Development Plan	TOR	Terms of Reference
ILI	Influenza-like Illness	UNICEF	United Nations Children's Fund
IPPP	Influenza Pandemic Preparedness Planning	US CDC	United States Centers for Disease Control and Prevention
ISID	International Society for Infectious Diseases	US HHS	United States Department of Health and Human Services
ISST	Infectious Substances Shipping Training	VCM	Vaccine Composition Meeting
IVPP	Influenza Virus with Pandemic Potential	WER	Weekly Epidemiological Record
IVTM	Influenza Virus Traceability Mechanism	WHA	World Health Assembly
L&S	Laboratory and Surveillance Capacity Building	WPR	WHO Western Pacific Region
LMIC	Low and Middle Income Countries	WHO	World Health Organization
MS	Member State		
NIC	National Influenza Centre		

IMPLEMENTATION OVERVIEW

PIP PC collection

PERCENTAGE OF TOTAL PC RECEIVED BY YEAR OF INVOICE



^a In 2012, contributions were made voluntarily

^b Figure includes PSC. PC collection for previous unpaid contributions and 2018 invoices is in process

TARGET
28M
/YEAR

\$170M

CONTRIBUTED BY
INDUSTRY^b

PIP PC financial implementation

PREPAREDNESS


BIENNIAL BUDGET: **\$31M**

FUNDED: **\$16M**

IMPLEMENTED: **\$11.4M**

IMPLEMENTATION BY HLIP II OUTPUT

US\$ in thousands



PIP SECRETARIAT

BIENNIAL BUDGET: **\$6.8M**

FUNDED: **\$2.8M**

IMPLEMENTED: **\$2.4M**

RESPONSE

TOTAL IN RESERVE
(WITH PSC & 2018
INTEREST): **\$46.7M**

LEGEND

Biennial budget
Funded
Implemented

PIP Framework outcome indicators

OUTCOME

Improved global pandemic influenza preparedness and response through the implementation of the PIP Framework

Indicator	2017 Baseline	2018 Status	2019 Target
% of Member States with zoonotic influenza cases sharing IVPPs with GISRS (N=4)	N/A	75%	N/A
% of PC recipient Member States reporting to FluNet (sustainability indicator) (N=37) ¹	84%	89%	≥85%
% of PC recipient Member States reporting to FluID (N=37) ¹	51%	73%	60%
% of Member States with BOD estimates considered by NITAG (N=19)	N/A	16%	30%
No. of PC recipient Member States that have implemented regulatory approach	0	6	10
% of PC recipient Member States that developed or updated a pandemic influenza preparedness plan (N=40) ¹	30%	35%	60%
% of companies reached to negotiate that signed an SMTA2 (N=32)	34%	38%	50%
% of Partnership Contributions received in the year of invoice (N=\$28M)	N/A	54%	100%

PIP Biological Materials^a shared

PIP BMs RECORDED IN IVTM



FROM 1 SEPTEMBER 2017 TO
31 AUGUST 2018:

184

VIRUS SUBTYPES RECORDED:
A(H1), A(H3), A(H5), A(H7), A(H9)



TOTAL SINCE 1 DECEMBER 2012:

844

PIP BMs RECORDED

^a For definition of 'PIP Biological Materials', see PIP Framework Section 4.1

SMTA2

SMTA2 WITH VACCINE & ANTIVIRAL MANUFACTURERS

Large / multi-national
manufacturers

>75M

pandemic production



Medium-sized
manufacturers

>5M and <75M

pandemic production



Small
manufacturers

<5M

pandemic production



>400M
DOSES

SMTA2 WITH DIAGNOSTIC MANUFACTURERS & ACADEMIC AND RESEARCH INSTITUTIONS



10M

TREATMENT COURSES OF
ANTIVIRALS



250,000

DIAGNOSTIC KITS



NEW:

25M

SYRINGES



66

SMTA2 WITH ACADEMIC
& RESEARCH INSTITUTIONS



29

BENEFIT-SHARING OFFERS
ACADEMIC & RESEARCH
INSTITUTIONS

PIP Framework governance

On 11-13 April and 17-19 October 2018, the PIP Advisory Group held its meetings in Geneva, which included consultations with industry and other PIP Framework stakeholders.



On 10 April 2018, the Secretariat held an Information Session on GISRS and the PIP Framework. The session was attended by more than 40 Member States and a wide range of stakeholders. The webcast from the session can be found at:
http://www.who.int/influenza/pip/10_April_Info_Session/en/

The Secretariat circulated a draft Analysis on the scope of the PIP Framework as requested by the World Health Assembly in Decision 70(10). This draft was discussed by Member States and stakeholders at the 15-16 October 2018 consultation on the implementation of Decision WHA70(10)8b. The final text was submitted for discussion by the 144th WHO Executive Board in 2019.

IMPLEMENTATION PROGRESS

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25292

